RYORLO Trademark

Trademark Overview

On Monday, November 11, 2013, a trademark application was filed for RYORLO with the United States Patent and Trademark Office. The USPTO has given the RYORLO trademark a serial number of 86115344. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 12, 2021. This trademark is owned by Celgene Corporation. The RYORLO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of blood disease and cancer
ryorlo

General Information

Serial Number86115344
Word MarkRYORLO
Filing DateMonday, November 11, 2013
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 12, 2021
Registration Number4579107
Registration DateTuesday, August 5, 2014
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 20, 2014

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, cytokine inhibitory drugs; pharmaceutical preparations that modulate the immune system; pharmaceutical preparations for the treatment of blood disease and cancer

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 12, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Thursday, November 14, 2013NEW APPLICATION ENTERED
Friday, November 22, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 25, 2014ASSIGNED TO LIE
Monday, February 24, 2014TEAS VOLUNTARY AMENDMENT RECEIVED
Monday, March 17, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 26, 2014ASSIGNED TO EXAMINER
Tuesday, March 4, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, March 4, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 5, 2014NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 5, 2014NON-FINAL ACTION WRITTEN
Wednesday, March 5, 2014NON-FINAL ACTION E-MAILED
Friday, March 7, 2014TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 17, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 17, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, April 30, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, March 20, 2014PREVIOUS ALLOWANCE COUNT WITHDRAWN
Sunday, March 23, 2014SUSPENSION LETTER WRITTEN
Sunday, March 23, 2014LETTER OF SUSPENSION E-MAILED
Sunday, March 23, 2014NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, April 1, 2014TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, April 8, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 8, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 10, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, April 11, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, May 20, 2014PUBLISHED FOR OPPOSITION
Tuesday, May 20, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 5, 2014REGISTERED-PRINCIPAL REGISTER
Wednesday, July 29, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 5, 2019COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, March 12, 2021CANCELLED SEC. 8 (6-YR)

Related Keywords

ryorlo pharmaceutical preparations treatment blood disease cancer system modulate namely cytokine